摘要
霍奇金淋巴瘤(HL)的Reed-Sternberg细胞可特征性表达CD30,而CD30在正常细胞中很少表达。CD30能快速内化,使其成为单克隆抗体和抗体-药物偶联物的理想靶标。维布妥昔单抗(BV)是新型靶向CD30的抗体偶联药物,其在HL的治疗史上具有里程碑式的意义。文章阐述BV作为巩固治疗、挽救治疗和联合用药在HL中的有效性、耐受性和安全性。
Reed-Sternberg cells of Hodgkin lymphoma(HL)typically express CD30,while CD30 is rarely expressed in normal cells and can be rapidly internalized,making it an ideal target for monoclonal antibodies and antibody-drug conjugates.Brentuximab vedotin(BV)is a novel CD30-directed antibody-conjugated drug,and it is a landmark in HL treatment history.This article will describe the efficacy,tolerability and safety of BV as consolidation,salvage and combination therapy in HL.
作者
于颖
邱录贵
易树华
Yu Ying;Qiu Lugui;Yi Shuhua(Institute of Hematology&Blood Diseases Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,National Clinical Research Center for Blood Diseases,State Key Laboratory of Experimental Hematology,Tianjin 300020,China)
出处
《白血病．淋巴瘤》
CAS
2020年第9期519-524,共6页
Journal of Leukemia & Lymphoma
基金
国家自然科学基金(81970187、81630007)
中国医学科学院医学与健康科技创新工程(CAMS-2016-I2M-3-013)。
